

# Jeffrey A Longmate

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2811401/jeffrey-a-longmate-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65  
papers

4,248  
citations

34  
h-index

65  
g-index

65  
ext. papers

4,563  
ext. citations

5  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
65	Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 541-548	4.9	3
64	Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology. <i>Current Problems in Cancer</i> , <b>2020</b> , 44, 100583	2.3	2
63	MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. <i>Blood</i> , <b>2017</b> , 129, 114-125	2.2	52
62	Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. <i>Transplantation</i> , <b>2016</b> , 100, 210-6	1.8	9
61	Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1004524	7.6	87
60	A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. <i>Journal of Virology</i> , <b>2013</b> , 87, 1322-32	6.6	74
59	Loss of T cell progenitor checkpoint control underlies leukemia initiation in Rag1-deficient nonobese diabetic mice. <i>Journal of Immunology</i> , <b>2013</b> , 190, 3276-88	5.3	3
58	A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 835-43	3.5	31
57	Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 1294-304	7	74
56	Toxicity equivalence range design (TEQR): a practical Phase I design. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 114-21	2.3	15
55	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. <i>Blood</i> , <b>2011</b> , 118, 2159-69	2.2	14
54	Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. <i>Transplant International</i> , <b>2011</b> , 24, 920-31	3	21
53	Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 33-7	4.9	15
52	A phase II trial of gefitinib and pegylated IFN $\gamma$ in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , <b>2011</b> , 16, 494-9	4.2	9
51	Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. <i>Journal of Virology</i> , <b>2011</b> , 85, 2878-90	6.6	40
50	Three ways of combining genotyping and resequencing in case-control association studies. <i>PLoS ONE</i> , <b>2010</b> , 5, e14318	3.7	7
49	Identification of high risk DISC1 protein structural variants in patients with bipolar spectrum disorder. <i>Neuroscience Letters</i> , <b>2010</b> , 486, 136-40	3.3	27

48	Evidence for X-chromosomal schizophrenia associated with microRNA alterations. <i>PLoS ONE</i> , <b>2009</b> , 4, e6121	3.7	76
47	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 777-83	3.5	229
46	A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 179-84	2.4	75
45	Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. <i>Blood</i> , <b>2009</b> , 113, 6465-76	2.2	114
44	Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 25-33	7	57
43	Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2008</b> , 31, 317-22	2.7	36
42	The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. <i>Clinical Genitourinary Cancer</i> , <b>2007</b> , 5, 433-7	3.3	78
41	Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 633-44	7	81
40	In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. <i>Experimental Hematology</i> , <b>2006</b> , 34, 497-507	3.1	21
39	Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 1410-21	7	42
38	A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1556-63	12.9	56
37	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 126-134	8.9	25
36	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 126-34	8.9	11
35	Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. <i>Biology of Blood and Marrow Transplantation</i> , <b>2005</b> , 11, 890-902	4.7	22
34	Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. <i>Vaccine</i> , <b>2005</b> , 23, 3453-68	4.1	33
33	Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 977-84	7	26
32	Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4876-80	2.2	9
31	The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4444-50	12.9	86

30	Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. <i>Cancer Research</i> , <b>2004</b> , 64, 962-8	10.1	252
29	Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. <i>Cancer Research</i> , <b>2004</b> , 64, 5407-14	10.1	40
28	Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. <i>Journal of Virology</i> , <b>2004</b> , 78, 3965-76	6.6	65
27	Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 461-7	12.9	64
26	Analysis of imprinting in mice with uniparental duplication of proximal chromosomes 7 and 15 by use of a custom oligonucleotide microarray. <i>Mammalian Genome</i> , <b>2004</b> , 15, 199-209	3.2	13
25	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 283-9	3.5	7
24	Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. <i>Cancer</i> , <b>2004</b> , 100, 2125-31	6.4	103
23	Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. <i>Clinical Lung Cancer</i> , <b>2004</b> , 6, 102-7	4.9	9
22	Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. <i>Human Immunology</i> , <b>2004</b> , 65, 476-85	2.3	73
21	Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. <i>Blood</i> , <b>2004</b> , 104, 847-56	2.2	40
20	CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. <i>Journal of Immunology</i> , <b>2003</b> , 170, 3401-7	5.3	75
19	Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. <i>Journal of Immunology</i> , <b>2003</b> , 171, 4028-39	5.3	26
18	Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 2362-78	4.8	238
17	Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. <i>Human Immunology</i> , <b>2003</b> , 64, 440-52	2.3	83
16	Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 908-18	7	14
15	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2002</b> , 50, 353-9	3.5	8
14	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 47, 327-32	3.5	8
13	Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 48, 22-8	3.5	17

12	Variations of dose and electrode spacing for rat breast cancer electrochemical treatment. <i>Bioelectromagnetics</i> , <b>2001</b> , 22, 205-11	1.6	24
11	Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 256-67	7	25
10	Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. <i>Journal of Virology</i> , <b>2001</b> , 75, 3048-52	6.6	84
9	Complexity and power in case-control association studies. <i>American Journal of Human Genetics</i> , <b>2001</b> , 68, 1229-37	11	82
8	Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. <i>Gynecologic Oncology</i> , <b>2000</b> , 77, 433-8	4.9	18
7	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2000</b> , 46, 19-26	3.5	80
6	Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up. <i>Gynecologic Oncology</i> , <b>1999</b> , 75, 419-26	4.9	8
5	Multiplex inheritance of component phenotypes in a murine model of lupus. <i>Mammalian Genome</i> , <b>1999</b> , 10, 176-81	3.2	78
4	Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 304-10	15.1	277
3	Speed congenics: a classic technique in the fast lane (relatively speaking). <i>Trends in Immunology</i> , <b>1997</b> , 18, 472-7		277
2	The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. <i>American Journal of Surgical Pathology</i> , <b>1997</b> , 21, 1409-19	6.7	165
1	Polygenic control of susceptibility to murine systemic lupus erythematosus. <i>Immunity</i> , <b>1994</b> , 1, 219-29	32.3	435